A review of Australian approaches for monitoring, assessing and reporting estuarine condition: III. Evaluation against international best practice and recommendations for the future

In this final component of a three-part review, we present a national synthesis and evaluation of approaches for monitoring, assessing and reporting estuarine condition across Australia. Progress is evaluated against objective criteria that together provide a model of international best practice. We critically assess the limitations, inconsistencies and gaps that are evident across Australian jurisdictions, and identify common obstacles to future progress. Major strengths and successes are also highlighted, together with specific examples of best practice from around Australia that are transferable to other States and beyond. Significant obstacles to greater national coordination of monitoring and reporting practices include inconsistent spatial scales of management, pluralistic governance structures and the lack of any overarching legislation. Nonetheless, many perceptible advances have been made over the last decade across Australia in estuarine monitoring and health assessment, and there is great potential for further progress. Finally, we provide a list of recommendations to address some of the most pressing limitations and gaps, and support improved future monitoring, assessment and reporting for Australian estuaries

A review of Australian approaches for monitoring, assessing and reporting estuarine condition: I. International context and evaluation criteria

© 2016 Elsevier Ltd Given the immeasurable value of estuaries and their severe and growing pressures, sound understanding and reporting of estuarine condition is essential for their effective management and sustainable development. In light of this, we aim to provide a timely and comprehensive three-part review of the approaches currently employed for monitoring, assessing and reporting estuarine condition, focussing on Australian systems. Here, in Part 1, we establish the national and international context of our review and define globally-relevant evaluation criteria against which to assess Australian progress. We achieve this by examining effective monitoring, assessment and reporting programs from around the world and characterising ‘best practice’. We then highlight the Australian historical context and consider recent policies, frameworks, guidelines and legislation relating to the monitoring and reporting of estuarine condition nationwide

‘... per eccesso di storia e di Luce’ : Il Mediterraneo di Francesco Biamonti

Un rapporto profondo quello di Biamonti con il Mediterraneo, fatto di nostalgia, silenzi, sguardi. E forse non poteva essere altrimenti per uno che nell’estremo ponente ligure è nato ed è vissuto, con gli occhi fissi all’azzurro luminoso del mare, tra rocce scoscese e terrazze di ulivi. Questo appartato angolo di Liguria è stato per Biamonti l’osservatorio privilegiato da cui guardare un paesaggio aspro e fragile che è nello stesso tempo reale ed esistenziale, e riflettere su tutto un mondo mediterraneo che sta cambiando, minacciato dall’incuria e percorso da tensioni sotterranee che rischiano di annientarlo. Unici punti di forza per resistere al degrado diventano allora il valore della storia e del sapere comuni, di ieri e di oggi, delle rive di qua e delle rive di là di un mare che corrode ma, comunque, veicola cultura e crea identità.peer-reviewe

B cells in SLE. Different biological drugs for different pathogenic mechanisms

Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease characterized by a complex multi-factorial pathogenesis and a great clinical polymorphism. SLE is considered to be a B cell disease in which autoantibodies are the major players. Recently, the central role of B cells has been confirmed and it has been shown that that the relative frequency of B cells subsets is altered in SLE patients. Conventional immunosuppressive therapies such as azathioprine, cyclophosphamide or methotrexate, reduce disease activity and improves the patient's general health conditions. These treatments have possible side effects; in fact they could compromise liver function, fertility and innate and adaptive immune responses. Moreover, for unknown reasons a small group of SLE patients is refractory to immunosuppressive therapy. In these cases finding an effective treatment becomes a challenge. The progress in therapeutic antibody technology has led to the production of a wide array of humanized monoclonal antibodies, targeting specific cell types or pathways, initiating a new era in the treatment of autoimmune disorders. In contrast to general immuno-suppression, the availability of drugs interfering with specific pathogenetic pathways gives the possibility to choose therapies tailored to each disease in each patient. © 2007 Elsevier B.V. All rights reserved

Sleep quality in patients with primary Sjögren's syndrome

Objective To assess the sleep quality in primary Sjögren’s syndrome (pSS) patients and evaluate its relationship with the disease, quality of life and mood disorders. Methods The sleep quality of 29 pSS women and 29 matched controls was assessed by the Pittsburgh Sleep Quality Index (PSQI). Seven domains are grouped according to three factors: F1 perceived sleep quality (subjective sleep quality, sleep latency, use of sleeping medication), F2 sleep efficiency (sleep duration, habitual sleep efficiency) and F3 daily disturbances (sleep disturbances, daytime dysfunction). These domains are scored as a single factor of global sleep quality. The Short Form Health Survey (SF-36), Functional Assessment of Chronic Illness Therapy (FACIT) fatigue scale and Hospital Anxiety and Depression Scale (HADS) were also administered. Disease activity and damage were evaluated with the EULAR Sjögren’s syndrome disease activity index (ESSDAI), the Sjögren’s Syndrome Disease Activity and Damage Indexes (SSDAI, SSDDI). Results The mean PSQI global score had higher pathological values (8.6±4.6) compared with controls (5.6±2.2) (p=0.002). F1 and F3 were significantly worse in cases (p=0.01, p=0.009). A negative correlation was found between SF-36 subscales and the global PSQI, F2 and F3. The anxiety HADS correlated with F2 and F3, while depression only with F3. No correlation with FACIT and disease indexes emerged. Conclusion Using PSQI, an impaired sleep quality was demonstrated in pSS patients, especially with perceived quality and the daily disturbances. It is associated with a reduced quality of life but not with disease-related variables.Objective To assess the sleep quality in primary Sjögren’s syndrome (pSS) patients and evaluate its relationship with the disease, quality of life and mood disorders. Methods The sleep quality of 29 pSS women and 29 matched controls was assessed by the Pittsburgh Sleep Quality Index (PSQI). Seven domains are grouped according to three factors: F1 perceived sleep quality (subjective sleep quality, sleep latency, use of sleeping medication), F2 sleep efficiency (sleep duration, habitual sleep efficiency) and F3 daily disturbances (sleep disturbances, daytime dysfunction). These domains are scored as a single factor of global sleep quality. The Short Form Health Survey (SF-36), Functional Assessment of Chronic Illness Therapy (FACIT) fatigue scale and Hospital Anxiety and Depression Scale (HADS) were also administered. Disease activity and damage were evaluated with the EULAR Sjögren’s syndrome disease activity index (ESSDAI), the Sjögren’s Syndrome Disease Activity and Damage Indexes (SSDAI, SSDDI). Results The mean PSQI global score had higher pathological values (8.6±4.6) compared with controls (5.6±2.2) (p=0.002). F1 and F3 were significantly worse in cases (p=0.01, p=0.009). A negative correlation was found between SF-36 subscales and the global PSQI, F2 and F3. The anxiety HADS correlated with F2 and F3, while depression only with F3. No correlation with FACIT and disease indexes emerged. Conclusion Using PSQI, an impaired sleep quality was demonstrated in pSS patients, especially with perceived quality and the daily disturbances. It is associated with a reduced quality of life but not with disease-related variables

Anticitrullinated protein/peptide antibodies and rheumatoid factors: two distinct autoantibody systems

In a previous issue of Arthritis Research and Therapy, Ursum and colleagues report the relative stabilities of anticitrullinated protein/peptide antibodies (ACPAs) and IgM rheumatoid factors during the course of rheumatoid arthritis and their differential correlation with markers of the acute-phase response. These findings add to a growing body of evidence highlighting the distinct nature of these two autoantibody systems and the role of ACPAs as a disease-specific marker of rheumatoid arthritis

The clearance of apoptotic cells: Implications for autoimmunity

Apoptosis has been clearly characterised by the ability to limit the activation of inflammatory responses through the disposal of the apoptotic cell by rapid uptake by phagocytes. The exposure of phosphatidylserine deriving from the loss of plasma lipid asymmetry is the early membrane signal which alerts the phagocyte about the imminent apoptotic death of the cell. Also modifications of membrane carbohydrate groups on apoptotic cells contribute to phagocyte recognition. Soluble proteins such as C1q, mannose-binding lectin, surfactant proteins A and D, C-reactive protein, C3bi, β2-glycoprotein I and growth arrest specific gene-6 bind to apoptotic cells and act as 'opsonins' thus favouring their clearance. A redundant and promiscuous system of receptors including integrins, scavenger receptors, CR3 and CR4, calreticulin, CD14 and Mer receptor ensures an efficient and rapid uptake of apoptotic cells. In animal models and in human pathology, single genetic defects of molecules involved in apoptotic cell clearance seem to be the main determinant in the development of autoimmunity. The uptake of apoptotic cells by phagocytes provides an immunomodulatory effect in that it triggers the release of anti-inflammatory cytokines, inhibits the production of inflammatory cytokines and leads to T cell tolerance. Impaired clearance of apoptotic cells or the presence of 'danger' signals may modify the balance between tolerance induction and activation of T cells leading to an effective autoimmune response. © 2002 Elsevier Science B.V. All rights reserved

Ecoengineering with Ecohydrology: Successes and failures in estuarine restoration

© 2016 Elsevier Ltd. Ecological Engineering (or Ecoengineering) is increasingly used in estuaries to re-create and restore ecosystems degraded by human activities, including reduced water flow or land poldered for agricultural use. Here we focus on ecosystem recolonization by the biota and their functioning and we separate Type A Ecoengineering where the physico-chemical structure is modified on the basis that ecological structure and functioning will then follow, and Type B Ecoengineering where the biota are engineered directly such as through restocking or replanting. Modifying the physical system to create and restore natural processes and habitats relies on successfully applying Ecohydrology, where suitable physical conditions, especially hydrography and sedimentology, are created to recover estuarine ecology by natural or human-mediated colonisation of primary producers and consumers, or habitat creation. This successional process then allows wading birds and fish to reoccupy the rehabilitated areas, thus restoring the natural food web and recreating nursery areas for aquatic biota. We describe Ecohydrology principles applied during Ecoengineering restoration projects in Europe, Australia, Asia, South Africa and North America. These show some successful and sustainable approaches but also others that were less than successful and not sustainable despite the best of intentions (and which may even have harmed the ecology). Some schemes may be 'good for the ecologists', as conservationists consider it successful that at least some habitat was created, albeit in the short-term, but arguably did little for the overall ecology of the area in space or time. We indicate the trade-offs between the short- and long-term value of restored and created ecosystems, the success at developing natural structure and functioning in disturbed estuaries, the role of this in estuarine and wetland management, and the costs and benefits of Ecoengineering to the socio-ecological system. These global case studies provide important lessons for both the science and management of estuaries, including that successful estuarine restoration is a complex and often difficult process, and that Ecoengineering with Ecohydrology aims to control and/or simulate natural ecosystem processes

Possible Implication of Red Blood Cells in the Prothrombotic Risk in Early Rheumatoid Arthritis

Rheumatoid arthritis (RA) is an autoimmune inflammatory disease that can be considered as a prothrombotic state1. A great number of studies have investigated the possible role of reactive oxygen species (ROS) in the etiology and pathogenesis of this disease. The presence of large amounts of superoxide radicals and hydrogen peroxide produced by activated neutrophils has been reported in the synovial fluid of patients with RA. This may cause lipid peroxidation that yields a wide variety of end products, including malondialdehyde (MDA), a known marker of oxidative stress. These products are therefore transported from the synovial fluid to the blood circulation system2. Considering that elevated levels of MDA have been observed in the blood plasma of patients with RA2, the aim of this pilot study was to investigate whether the elevated levels of plasmatic MDA could be associated with a modification of the total antioxidant capacity (TAC) of blood plasma that is usually indicative of a “systemic” oxidative imbalance3. In addition, in view of their activity as redox effectors or scavengers4, as well as determinants of thrombus formation5, we evaluated red blood cell (RBC) features in terms of their redox state and lifespan marker molecules

Changes in T cell effector functions over an 8-year period with TNF antagonists in patients with chronic inflammatory rheumatic diseases

The aim of the study was to clarify the effect of long-term anti-TNF therapy on T cell function in patients with rheumatologic immune-mediated inflammatory diseases (IMID). The production of IFNγ by T cells was evaluated at baseline and after 1, 2, 4, and 8 years of anti-TNF agents by means of a QuantiFERON-TB Gold In-Tube assay. The T cell proliferation and surface co-expression of CD25/CD134 in response to phytohaemagglutinin together with the in vitro impact of anti-TNF therapy on the functional capacity of T cells were evaluated after 8 years from the onset of the biological treatment. Age-matched healthy donors were enrolled as controls. The quantitative mitogen-induced IFNγ responses significantly increased with respect to baseline at each time point, apart from the determination after 4 years. We found an increased expression of CD25/CD134 in CD4+compared to CD8+T cells both in patients and controls. The in vitro addition of anti-TNF agents induced a significant decrease of both the IFNγ response and of CD25/CD134, whereas no effect on the intensity of the proliferative response was observed. Our data provide a biological basis for the reassuring issues on the safety of long-term anti-TNF treatment in patients with IMID